Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Tagawa, S. T. [1 ]
Sun, M. [2 ]
Sartor, O. [3 ]
Thomas, C. [4 ]
Molina, A. M. [1 ]
Sternberg, C. N. [5 ]
Nanus, D. M. [6 ]
Osborne, J. [7 ]
Bander, N. [8 ]
机构：
[1] Weill Cornell Med Ctr, Urol, Hematol & Med Oncol, New York, NY USA
[2] Weill Cornell Med Ctr, Hematol & Med Oncol, New York, NY USA
[3] Tulane Med Sch, Med Sch, New Orleans, AL USA
[4] Weill Cornell Med Ctr, Biostat, New York, NY USA
[5] Cornell Univ, Weill Cornell Med Coll, Dept Hematol & Oncol, New York, NY USA
[6] Weill Cornell Med Coll, Med, New York, NY USA
[7] Weill Cornell Med Ctr, Radiol, New York, NY USA
[8] Weill Cornell Med Ctr, Urol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600P
引用
收藏
页码：S645 / S645
页数：1
相关论文
共 50 条
  • [1] Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Thomas, Charlene
    Nauseef, Jones T.
    Sartor, A. Oliver
    Sun, Michael Philip
    Castellanos, Sandra Huicochea
    Fajardo, Andres Ricaurte
    Beltran, Himisha
    Demichelis, Francesca
    Sigouros, Michael
    Orlando, Francesco
    Molina, Ana M.
    Davidson, Zachary
    Patel, Amie
    Lewis, Brian E.
    Nanus, David M.
    Vallabhajosula, Shankar
    Bander, Neil Harrison
    Osborne, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Niaz, Muhammad Junaid
    Osborne, Joseph
    Vallabhajosula, Shankar
    Beltran, Himisha
    Harshman, Lauren Christine
    Nanus, David M.
    Molina, Ana M.
    Faltas, Bishoy Morris
    Hackett, Amy
    Gracey, Lauren
    Sreekumar, Jyothi
    Babich, John
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Osborne, J. R.
    Hackett, A.
    Niaz, M. J.
    Cooley, V.
    Christos, P.
    Vlachostergios, P. J.
    Thomas, C.
    Gracey, L.
    Beltran, H.
    Molina, A. M.
    Nanus, D. M.
    Babich, J.
    Vallabhajosula, S.
    Sartor, O.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Jhanwar, Y.
    Hackett, A.
    Oromendia, C.
    Naiz, M. J.
    Goldsmith, S. J.
    Nanus, D. M.
    Beltran, H.
    Molina, A. M.
    Faltas, B.
    Sreekumar, J.
    Babich, J.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [7] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Batra, Jaspreet
    Christos, Paulj.
    Jhanwar, Yuliya
    Goldsmith, Stanley J.
    Nanus, David M.
    Beltran, Himisha
    Molina, Ana M.
    Faltas, Bishoy
    Hackett, Amy
    Sreekumar, Jyothi
    Babich, John
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [9] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [10] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
12345